A Study of Distal Jejunal-release Dextrose in Obese Participants

Aphaia Pharma

Status and phase: Active, not recruiting; Phase 2

Conditions: Obese

Treatments: Drug: APHD-012; Drug: APHD-012P

Study type: Interventional

Funder types: Industry

Identifiers

NCT05385978

034B20

Details and patient eligibility

About

The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose [Aphaia technology, AT]) in obese participants.

Full description

This is a randomized, double-blind, placebo-controlled, parallel-group, phase II proof-of-concept study to be conducted in 150 adult obese male and female participants who are 18 to 70 years of age with or without one or more endocrine and/or metabolic conditions. The study aims to evaluate the efficacy and safety of distal jejunal-release dextrose (Aphaia technology, AT) in obese participants.

Participants will be randomly assigned to receive either APHD-012 (distal jejunal-release dextrose or APH-012P (a matching placebo). There will be two cohorts in the study. Participants from Cohort 1 will receive study medication once daily for 12 months (360 days), and participants from Cohort 2 will receive study medication once daily for 6 months (180 days).

Overall, 150 participants will be enrolled in the study:

• Cohort 1 (60 participants) - 6-month treatment period + 6-month maintenance treatment period
• Cohort 2 (90 participants) - 6-month treatment period

Enrollment: 150 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Body mass index 30.0-39.9 kg/m^2 and/or waist circumference: men >102 cm, women >88 cm

• Stable body weight: gain or loss in body weight ≤5 kg over last 3 months

• Obese participants with or without one or more of the following conditions:

  1. NAFLD - simple steatosis based on a FibroScan CAP™ test result at screening (CAP Score ≥238 decibel-milliwatts (dB/m) (Steatosis Grades 1-3) with no or mild fibrosis (F0-F1 fibrosis Score)
  2. NASH - steatohepatitis based on FibroScan fibrosis Score at screening (≥7.5 kPa and <14 kPa (Stage F2-F3)
  3. Confirmed medical history of metabolic syndrome
  4. Homeostatic Model Assessment of Insulin Resistance (HOMA IR) Score ≥2
  5. Confirmed medical history of type 2 diabetes mellitus (T2DM) diagnosis or HbA1c ≥7.0 and <11 (based on screening values)
  6. High total cholesterol ≥240 mg/dL (based on screening values)
  7. Hypertension (participants with Stage 1 hypertension (systolic blood pressure [SBP] ≥130 mmHg <180 mmHg, diastolic blood pressure [DBP] ≥80 mmHg <110 mmHg) (based on screening values)

• If on medication to manage endocrine/metabolic conditions, must be on stable doses of medication ≥3 months prior to screening:

  1. Participants with T2DM may be treated with either diet and exercise alone, metformin, sulphonylurea, thiazolidinediones, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and bromocriptine quick-release (QR) as single agents or combination therapy.
  2. As lipid-lowering medication participants may be treated with statins and fibrates, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, ezetimibe, or supplements like omega-3-fatty acids.
  3. As antihypertensive medication participants may be treated with beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II-inhibitors, diuretics, or calcium channel blockers.

• Normal GI function, or abnormalities which the clinical investigator does not consider a disqualification for participation in the study

Exclusion criteria

• Incomplete Coronavirus Disease of 2019 (COVID-19) vaccination

• Treatment with weight loss medications in the past 3 months

• Proven history of bulimia or anorexia nervosa

• Treatment with injectable antidiabetic medications in the last 3 months (e.g. Glucagon-like peptide-1 [GLP-1] receptor agonists, insulin)

• Treatment with dipeptidyl peptidase-4 inhibitors in the last 3 months

• NASH with cirrhosis (fibrosis Score=F4 (≥14 kPa) as determined by screening FibroScan

• Confirmed medical history of liver cirrhosis, cholestatic disease, alcohol-related liver disease

• Type 1 diabetes mellitus, HbA1c ≥11, fasting plasma glucose levels ≥270 mg/dL

• Proliferative retinopathy or maculopathy

• Abnormal liver function tests:

  1. Transaminases:

     • Alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥5 x upper limit of normal (ULN) for participants with NAFLD or NASH (as determined by screening FibroScan)
     • ALT/AST ≥2.5 x ULN for participants without NAFLD or NASH (as determined by screening FibroScan)

  2. Alkaline phosphatase (ALK) ≥2.5 x ULN

  3. Total bilirubin ≥2 x ULN

• Stage 4 hypertension (SBP ≥180, DBP ≥110)

• History or presence of any uncontrolled cardiovascular, pulmonary, hepatobiliary, renal, hematologic, gastrointestinal, endocrinologic, immunologic, dermatologic, neurological, psychiatric, metabolic, musculoskeletal, or malignant disease (except conditions accepted for inclusion) which the clinical investigator does not consider a disqualification for participation in the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

150 participants in 2 patient groups, including a placebo group

APHD-012

Active Comparator group

Description:

Participants will receive a single dose of APHD-012 12 g daily, under fasting conditions prior to main daily meals for 180 days (6 months) for Cohort 2 and for 360 days (12 months) for Cohort 1.

Treatment:

Drug: APHD-012

APHD-012P

Placebo Comparator group

Description:

Participants will receive a single dose of APHD-012P daily, under fasting conditions prior to main daily meals for 180 days (6 months) for Cohort 2 and for 360 days (12 months) for Cohort 1.

Treatment:

Drug: APHD-012P